Le Lézard
Classified in: Health
Subjects: SVY, AVO, FVT

94% of People With Glioblastoma Demand Healthcare Overhaul


NEW YORK, July 16, 2019 /PRNewswire/ -- 94% of people affected by glioblastoma see providing the "best treatment regardless of personal financial situation" and 55% see "the elimination of co-pays" as essential. These are the headline results from 400+ people surveyed by OurBrainBank.

The survey shows: 

GBM patients face a median survival of 14 months, and +5% survive five years. In nearly 100 years, only five new treatments have been approved.

Hundreds of comments poured in.

OurBrainBank founder Jessica Morris, living with GBM, will hand-deliver the findings to Capitol Hill on July 17.

Fabio Iwamoto MD, Deputy Director, Neuro-Oncology, Columbia University and chair of OurBrainBank's medical advisors, commented: "This survey and patient comments make for compelling reading ? people are rightly desperate for change."

Jessica Morris, founder OurBrainBank said, "Our survey shows imagination in the face of adversity ? we are a desperate community. I cannot think of a better way to honor the lives of those who have died from glioblastoma, by devoting our lives to make real change.

"OurBrainBank thanks the U.S. Senate for this important gesture."

In a rare showing of bipartisanship, the Glioblastoma Awareness Day Resolution was signed by Senators Elizabeth Warren (D-MA), Mitch McConnell (R-KY), Kyrsten Sinema (D-AZ), Lindsey Graham (R-SC), and Martha McSally (R-AZ).

It honors those we've lost and recognizes the challenges faced by people living with GBM. Public figures who've succumbed include Senators John McCain and Ted Kennedy; Beau Biden, and George Gershwin.

OurBrainBank is a patient-led movement designed to move glioblastoma from terminal to treatable, powered by patients. Our key tool is a free app which both enables people affected by GBM to manage their disease better and helps further research.

Contact: Martha Wilkie  2124637664, 218242@email4pr.com

OurBrainBank Advisors
Terri S. Armstrong PhD, NIH
Marina Benaur MD, Memorial Sloan Kettering
Alexis Demopoulos MD, Northwell Health
Bruce Hellman CEO, uMotif 
Fabio M. Iwamoto MD, Columbia University
Mario Lacouture MD, Memorial Sloan Kettering
Lakshmi Nayak MD, Dana-Farber Cancer Institute
Daniel A. Orringer MD, Michigan Medicine
Joshua Silverman MD, NYU Langone Health

Full release 
OurBrainBank.org 
Facebook.com/OurBrainBank + Facebook.com/groups/OurBrainBank
Twitter.com/OurBrainBank 
YouTube.com/c/OurBrainBankForGlioblastoma 
Instagram.com/OurBrainBankGorGlioblastoma 
Crowdrise (donate)

SOURCE OurBrainBank


These press releases may also interest you

at 14:02
On behalf of the Québec government, Minister of Tourism Caroline Proulx today announced the closing until further notice of tourist accommodation establishments. There are two exceptions to the rule: certain campgrounds that host snowbirds who do not...

at 14:00
Confluent Health is proud to announce their newest partnership, El Paso Physical Therapy Services (EPPTS), a physical therapist-owned rehabilitation company since 1985 specializing in the treatment of orthopedic, sports, and work-related injuries...

at 11:23
Today, Samaritan's Purse deployed its Emergency Field Hospital to New York City, New York, where the local medical infrastructure is severely overwhelmed. In cooperation with the Federal Emergency Management Agency (FEMA), New York state officials,...

at 11:01
Novartis today announced results from a prespecified analysis of pooled data from three Phase III studies evaluating the safety and efficacy of inclisiran, its first-in-class investigational treatment for hyperlipidemia in adults. The data was...

at 11:00
As the impact of the Coronavirus (COVID-19) is now felt worldwide, we want to assure our customers and partners that we are still here to support you. Zenner's operations remain open with regular operating hours. Zenner's number one priority is...

at 10:13
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg...



News published on 16 july 2019 at 13:24 and distributed by: